Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now small index

Hereditary Cancer Syndrome clinical trials

5 of 5 indexed Hereditary Cancer Syndrome trials are currently recruiting.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 5 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Hereditary Cancer Syndrome: 5 US clinical trials tracked, 5 recruiting.

Hereditary Cancer Syndrome is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. The most active sponsor is San Raffaele University, running 1 of these trials.

Enrollment posture brief

Registry condition hereditary-cancer-syndrome

OPEN 5 | RECR 100% | LATE 0 | EARLY 0 | RANK #3391 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Hereditary Cancer Syndro (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Hereditary Cancer Syndrome

Hereditary Cancer Syndrome lists 5 open slots (100% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Hereditary Cancer Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Hereditary Cancer Syndrome is recruiting above its size-band peers.

    5 of 5 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Hereditary Cancer Syndrome research.

    San Raffaele University accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.

  3. Typical Hereditary Cancer Syndrome enrolment sits around 300 participants.

    Median target enrolment is 300 among the 5 trials that report a genuine target (sentinel values excluded). 1 of those (20%) plan for fewer than 100 participants.

  4. Hereditary Cancer Syndrome splits between interventional and observational designs.

    3 interventional and 2 observational studies make up this index (60% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase Distribution

Phase data not available

Named interventions

Most-linked intervention names on Hereditary Cancer Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Enhanced Standard of Care Model Other
1 trials
Mainstream Genetic Testing Model Other
1 trials
Data and Specimen Collection Genetic
1 trials
LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System) Diagnostic test
1 trials
Obstetrical carrier screening Device
1 trials
Natera empower comprehensive hereditary cancer panel Device
1 trials
Chatbot Other
1 trials

US sites by state

Facility locations filed on Hereditary Cancer Syndrome trials. A trial with sites in several states counts in each.

New York 2 trials
Massachusetts 1 trials
Illinois 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Hereditary Cancer Syndrome page

5 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 5 Hereditary Cancer Syndrome trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • San Raffaele University sponsors the most Hereditary Cancer Syndrome trials on record, review their full trial history before evaluating a specific study. See San Raffaele University's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hereditary Cancer Syndrome condition card totals 5 registered trials; most-linked intervention Enhanced Standard of Care Model; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.